FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry, specifically to N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-ene-1-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(morpholine-4-yl)-1-((phenylsulphanyl)methyl)propyl)-amino)-3-((trifluoromethyl)sulphonyl)benzenesulphonamide (ABT-263) in a solid crystalline form. The invention also relates to a pharmaceutical composition on the basis of the above crystalline forms, suitable for the treatment of diseases, characterised by the apoptosis disorder and/or overexpression of one or more anti-apoptotic Bcl-2 family proteins.
EFFECT: obtained new crystalline forms of ABT-263 with useful biological properties.
35 cl, 2 dwg, 22 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SALTS AND CRYSTALLINE FORMS OF APOTTOSIS-INDUCING AGENT | 2011 |
|
RU2628560C2 |
| ABT-263 CAPSULE | 2010 |
|
RU2550956C2 |
| STABILISED LIPID PREPARATIVE FORM OF APOPTOSIS PROMOTER | 2010 |
|
RU2530642C2 |
| SOLID DISPERSIONS CONTAINING APOPTOSIS PROMOTING PROTEINS | 2010 |
|
RU2550134C2 |
| DASATINIB SALTS IN CRYSTALLINE FORM | 2014 |
|
RU2662805C2 |
| MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED COCRYSTAL FORMERS | 2013 |
|
RU2650524C2 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2568599C2 |
| CRYSTALLINE BROMODOMAIN INHIBITORS | 2014 |
|
RU2675268C2 |
